AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03111095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Health
Description: Subjects will submit blood pressure and weight measurements daily for 6 weeks postpartum. Subjects will have a video telehealth visit with the mobile health nurse at 48 hours and 7 days after discharge from the hospital.
Study NCT01238029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib and Capecitabine and Vinorelbine
Description: Dose finding Study Lapatinib: 1000-1250 oral, once daily, days 1-21 Capecitabine: 1000 mg/sqm oral, bid, days 1-14 Vinorelbine 10-22,5 mg/sqm, i.v. Day 1 + 8
Study NCT04500743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dienogest
Description: Group B (n=67) who had daily oral Dienogest 2 mg/d for 3 months before starting standard long protocol for IVF
Study NCT04500743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leuprorelin acetate
Description: Group A (n=67) who had monthly depot GnRHa for 3 months before ovarian stimulation in IVF treatment (Ultra-long protocol)
Study NCT04344990 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia - Group E
Description: Postoperative analgesia with continuous epidural infusion (control group) with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min)
Study NCT04344990 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral blockade - Group F
Description: Postoperative analgesia with continuous femoral nerve blockade infusion with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min) .
Study NCT04344990 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraarticular infusion - Group I
Description: Postoperative analgesia with continuous intraarticular infusion with Ropivacaine 0.2% + clonidine 150μg with PCA pump (2ml/h and bolus dosage 0,5ml per 15min)
Study NCT01648283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV racemic methadone HCl
Description: IV racemic Methadone HC1 6 mg
Study NCT01648283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral racemic methadone HCl
Description: oral d5-methadone HCl 11 mg
Study NCT00828620 — intervention group
Intervention type: OTHER
Intervention: Imaging study
Description: PET-CT
Study NCT02899637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active high-frequency Transcranial Magnetic Stimulation
Description: Active intervention, 5Hz on the lower limbs area of the motor cortex, during one week
Study NCT02899637 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham high-frequency Transcranial Magnetic Stimulation
Description: Sham intervention, 5Hz on the lower limbs area of the motor cortex, during one week
Study NCT02060279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention and carotenoid supplements
Description: 2 week intervention partial hospitalization program followed by 8 bi-monthly sessions of a lifestyle intervention group run by a psychologist or health coach (research assistant). The entire intervention will last approximately 6 months. Children will participate in all aspects of the intervention including: dietary groups, life coaching, art and music therapy, school based learning, group therapy, physical activity, cooking, preparing meals, family therapy sessions, and yoga. The participants randomized to this study arm will also take Jarrow Formulas CaroteneAll® (5000 IU) supplement while at the intervention site for 2 weeks and then will continue to take the supplements for up to 6 months until their participation in the study is complete. Two capsules of supplement will be consumed daily with a meal with 6 oz. of water.
Study NCT02060279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention and placebo
Description: 2 week intervention partial hospitalization program followed by 8 bi-monthly sessions of a lifestyle intervention group run by a psychologist or health coach (research assistant). The entire intervention will last approximately 6 months. Children will participate in all aspects of the intervention including: dietary groups, life coaching, art and music therapy, school based learning, group therapy, physical activity, cooking, preparing meals, family therapy sessions, and yoga. The participants randomized to this study arm will also take a gel-cap placebo while at the intervention site for 2 weeks and then will continue to take the placebo for up to 6 months until their participation in the study is complete. Two capsules of placebo will be consumed daily with a meal with 6 oz. of water.
Study NCT03506490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercises
Description: The training session lasted 45 minutes and was composed of running exercises.
Study NCT02900404 — intervention group
Intervention type: OTHER
Intervention: XAPPORT
Description: A mobile device app based on different guidelines provides adequate guidance to physicians attending patients undergoing elective surgery, who have to interrupt treatment with rivaroxaban for surgery, in deciding how to approach the pre- and postoperative management of anticoagulation.
Study NCT03487549 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VP-102 Cantharidin topical film forming solution
Description: VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 14 days between treatments.
Study NCT03487549 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VP-102 Cantharidin, topical film forming solution
Description: VP-102, a single-use drug device combination product containing (cantharidin) topical solution, 0.7% (w/v). Treatment interval of at least 21 days between treatments.
Study NCT01793831 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FMT
Description: Standard FMT
Study NCT02900404 — intervention group
Intervention type: OTHER
Intervention: Expert Panel (gold standard)
Description: A national panel of experts comprising anesthetists and surgeons from various disciplines advised in developing an algorithm supporting physicians how to approach the perioperative management of anticoagulation in patients receiving rivaroxaban and requiring elective surgery.
Study NCT03366194 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SkinStylus Sterilock System
Description: Microneedling device will be used to treat ventral hypertrophic scars.
Study NCT03394833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gelofusine
Description: Preoperative colloid fluid bolus 6ml/kg ideal body weight
Study NCT02585622 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stromal Cells
Description: Cells will be administered intravenously at 3 different doses (80, 160, or 240 x 10\^6, fixed dose) over 10-20 minutes. Volume total of fluid infused: 40 ml
Study NCT02585622 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Volume total of fluid infused: 40 ml
Study NCT03514017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously (IV) at 200 mg every 3 weeks for 1 year and up to 2 years.
Study NCT03514017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be administered orally once daily at approximately the same time each day at the dose of 420 mg daily (3 capsules of 140 mg daily).
Study NCT02452229 — intervention group
Intervention type: OTHER
Intervention: Review of the Literature for Human Herpes Virus infections
Description: Review of the Medline database (PubMed and Ovid interface) for human herpes virus infections in burns as well as Web of Science interface.~PRIMSA (preferred reporting items for systematic reviews and meta-analyses) guidelines and checklist were used.
Study NCT01112735 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FS VH S/D 4 s-apr (= two-component fibrin sealant, double virus inactivated, made from pooled human plasma)
Description: Dosage form: spray (aerosolized sealant), Dosage frequency: once (1 layer). ARTISS will be applied onto the fascia or the wound bed.
Study NCT01112735 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of care
Description: Standard of care
Study NCT01997840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone
Description: ACY-1215 (Ricolinostat) 160mg QD Days 1-21 with pomalidomide 4mg QD Days 1-21 and dexamethasone 40mg QD Days 1,8,15,22 of a 28-day cycle
Study NCT02347917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: 480 mg orally twice daily (960 mg total daily dose)
Study NCT02347917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for cycle 1, in which Pemetrexed will be given on Day 3).
Study NCT02347917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for Cycle 1, in which Cisplatin will be given on Day 3).
Study NCT01051778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin 40mg plus low dose aspirin
Description: Enoxaparin 40mg/day by subcutaneous injection ( Clexane 40 mg, Aventis international, Sanofi-aventis France ) is started when the serum pregnancy test become positive. Enoxaparin is stopped 2 days before planned induction of labor or cesarean section and twice-daily unfractionated heparin (UFH) is initiated. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop enoxaparin or UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID)) is started before conception and continued until 36 weeks gestation.
Study NCT01051778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin calcium5,000 U twice daily plus low dose aspirin
Description: Heparin Calcium 5,000 U twice daily (Cal-Heparine, Amoun Pharmaceutical Co, Egypt) by subcutaneous injection is started when the serum pregnancy test become positive. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID))is started before conception and continued until 36 weeks gestation .
Study NCT02005666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel
Description: Drug:-1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of Cadila healthcare limited Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
Study NCT02005666 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DUAC® Gel
Description: Drug:-DUAC® Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
Study NCT02005666 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug:-Placebo, Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
Study NCT03288350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mDCF + Avelumab
Description: Patients will receive neoadjuvant therapy consisting of 4 cycles of avelumab added to the modified chemotherapy regimen of docetaxel, cisplatin, 5-fluorouracil (mDCF), followed by surgery and assessment of pathologic response. Then they will receive 4 cycles of adjuvant therapy of mDCF and avelumab.
Study NCT00927342 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vivostat
Description: Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Vivostat sealant applied to the surface of the lung in an attempt to eliminate air leak
Study NCT00927342 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BioGlue
Description: Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Bioglue sealant applied to the surface of the lung in an attempt to eliminate air leak
Study NCT04017884 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Remin Pro Forte
Description: a combination of chemicals with natural products cream .
Study NCT04017884 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Remin Pro
Description: a combination of chemicals
Study NCT01982019 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Meal test taking and hormones measure including 26RFa
Description: Meal test taking and blood sampling for the measure of 26RFa and classical hormones implicated in glucose control and obesity
Study NCT03192085 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SITA FAST VISUAL FIELD TEST
Description: Diagnostic test for glaucoma
Study NCT03192085 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: SITA FAST VISUAL FIELD TEST
Description: Diagnostic test for glaucoma
Study NCT03192085 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SITA STANDARD VISUAL FIELD TEST
Description: Diagnostic test for glaucoma
Study NCT03192085 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: SITA STANDARD VISUAL FIELD TEST
Description: Diagnostic test for glaucoma
Study NCT01475487 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Utrasound guided cricothyrotomy
Description: Utrasound guided cricothyrotomy
Study NCT01475487 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Utrasound guided cricothyrotomy
Description: Utrasound guided cricothyrotomy
Study NCT01948401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA
Description: long-acting beta-agonist treatment
Study NCT01495637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF is to be administered IV at one of four possible dosing regimens (three days at a dose of 30, 62, or 125 mcg/m2 per day, or an extended dosing regimen of 125 mcg/m2/day through post-trauma 6) if severe innate immune suppression is identified on post-trauma days 1, 2, or 3.
Study NCT04140058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: ondansetron was administered 20 minutes prior to spinal anesthesia.
Study NCT04140058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo of 10 mL normal saline was administered.
Study NCT02992275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Description: Participants will receive NMES to the hip abductors while performing strength training 3 times per week for 24 weeks
Study NCT02992275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-Modality Balance Intervention (MMBI)
Description: Participants will attend a group balance class that focuses on movement and obstacle negotiation 3 times per week for 24 weeks
Study NCT06708442 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: School-based CBT intervention
Description: School-based CBT intervention: a 3-day, 40-minute per day cognitive behavioral intervention. The intervention will take place in a school classroom in a format similar to offline classroom lectures and classroom interactions. The intervention will lead by one undergraduate student from the School of Psychological and Cognitive Sciences and one first-year doctoral student with training in clinical psychology. The content of the intervention was based on the theory of cognitive behavioral therapy for children, with a complete self-developed intervention manual, and three interventions targeting emotional awareness and management, thought recognition, and problem coping, respectively.
Study NCT06708442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-based CBT intervention
Description: School-based CBT intervention: a 3-day, 40-minute per day cognitive behavioral intervention. The intervention will take place in a school classroom in a format similar to offline classroom lectures and classroom interactions. The intervention will lead by one undergraduate student from the School of Psychological and Cognitive Sciences and one first-year doctoral student with training in clinical psychology. The content of the intervention was based on the theory of cognitive behavioral therapy for children, with a complete self-developed intervention manual, and three interventions targeting emotional awareness and management, thought recognition, and problem coping, respectively.
Study NCT06708442 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Narrative Technique (GNT) Writing
Description: Guided Narrative Technique (GNT) Writing : GNT writing is an intervention through writing. It will be conducted once a day for 20-30 minutes for three days. Subjects will be asked to complete Guided Narrative Writing at a set time each day for three consecutive days, under the guidance and supervision of a school teacher, following guidelines.
Study NCT06708442 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided Narrative Technique (GNT) drawing
Description: Guided Narrative Technique (GNT) Drawing: GNT drawing is an intervention through drawing. It will be conducted once a day for 20-30 minutes for three days. Subjects will be asked to complete Guided Narrative Drawing at a set time each day for three consecutive days, under the guidance and supervision of a school teacher, following guidelines.
Study NCT06709729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin pump with closed-loop system
Description: Device: Usage of Insulin pump t:slim X2 with Control-IQ technology or MiniMed 780G with Smartguard technology in previous users of AndroidAPS
Study NCT04092270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04092270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT04092270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT04092270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04092270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan
Study NCT04092270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV
Study NCT04092270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Given PO
Study NCT04180085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept Injection
Description: 9 injections of belatacept at 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months 11 months and 12 months post graft
Study NCT01948401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: chronic treatment with oral corticosteroids, high dose inhaled corticosteroids
Study NCT03211338 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Culture with progesterone
Description: Progesterone, a steroid hormone will be cultured with placental IMC cells or peripheral blood CD14+ monocyte cells
Study NCT02403323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrolizumab
Description: 105 mg etrolizumab subcutaneous administration once every 4 weeks
Study NCT00506519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithrombin alfa (INN name)
Study NCT00506519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control (Standard treatment)
Study NCT04215978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-A445
Description: Administered as specified in the treatment arm
Study NCT03211338 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Culture without progesterone
Description: Culture of placental IMC cells or peripheral blood CD14+ monocyte cells without progesterone
Study NCT03211338 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Culture with growth factors
Description: Culture of placental IMC cells with growth hormones only and analysis
Study NCT02999399 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brussel Sprouts
Description: Subjects are given \~150 g of Brussels sprouts once daily for 7 consecutive days.
Study NCT02999399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuterated Phenanthrene
Description: Subjects are given 1 microgram of deuterated phenanthrene \[D10\]phe at baseline and after 7 days of Brussels sprout consumption. Urine is collected for 6 hours after each dose.
Study NCT02862899 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermowire
Study NCT01927341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: Tablet for oral use, 45 mg (three 15 mg tablets), BID
Study NCT01927341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Intravenous infusion, 20mg/ml concentrate solution for infusion, Q2W (Days 1 and 15 of every cycle)
Study NCT04215978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab
Description: Administered as specified in the treatment arm